Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.

OBJECTIVE The risk of cardiovascular disease (CVD) is increased in patients with rheumatoid arthritis (RA), most likely because of increased systemic inflammation. Prior research suggests that immunosuppressive medications may reduce the risk of CVD among RA patients. This study was undertaken to investigate the effects of various immunosuppressive medications on the risk of cardiovascular events among a group of older patients with RA. METHODS In this nested case-control study, the source cohort was derived from Medicare beneficiaries receiving a drug benefit from the state of Pennsylvania. These individuals were required to have been diagnosed as having RA on at least 2 visits and to have filled a prescription for an immunosuppressive agent. Cases were defined as those patients who were hospitalized for a cardiovascular event such as myocardial infarction or stroke, and 10 control subjects were matched to each case by age, sex, and calendar year of the index date (the time of the first cardiovascular event in each case). Current use of an immunosuppressive medication was defined as having filled a prescription for these agents within the 90 days prior to the index date. Multivariate logistic regression models that included important covariates were assessed to determine the risk of cardiovascular events associated with immunosuppressive agents and their combinations. RESULTS Among the study cohort, we identified 3,501 RA patients who fulfilled our eligibility criteria. During followup of this cohort, 946 patients were hospitalized for a cardiovascular event. Although the 95% confidence intervals (95% CIs) were wide in adjusted risk regression models with methotrexate (MTX) monotherapy as the reference group, biologic immunosuppressive agents showed neither protective nor deleterious effects (with biologics monotherapy, odds ratio [OR] 1.0, 95% CI 0.5-1.9; with biologics plus MTX combination therapy, OR 0.8, 95% CI 0.3-2.0; and with biologics plus other immunosuppressive agents, OR 1.2, 95% CI 0.7-2.2). Monotherapy with oral glucocorticoids was associated with an increased risk of cardiovascular events (OR 1.5, 95% CI 1.1-2.1), and a similar trend in the direction of risk was seen with glucocorticoid combination therapy (OR 1.3, 95% CI 0.8-2.0). Cytotoxic immunosuppressive agents other than MTX (azathioprine, cyclosporine, and leflunomide) were also associated with an increased risk of cardiovascular events (with both monotherapy and combination treatment, OR 1.8, 95% CI 1.1-3.0). CONCLUSION When compared with RA patients receiving MTX monotherapy, those receiving biologic immunosuppressive agents had neither an increased nor decreased risk of experiencing a cardiovascular event, whereas use of oral glucocorticoids and cytotoxic immunosuppressive agents was associated with significant increases in the risk of cardiovascular events.

[1]  M. Hudson,et al.  Antirheumatic drug use and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.

[2]  G. McColl,et al.  Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. , 2005, Rheumatology.

[3]  Paul Wordsworth,et al.  BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. , 2005, Rheumatology.

[4]  M. González-Gay,et al.  High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[5]  B. Gage,et al.  Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors , 2005, Medical care.

[6]  M. Hudson,et al.  Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. , 2005, Rheumatology.

[7]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[8]  S. Gabriel,et al.  Cardiovascular death in rheumatoid arthritis: a population-based study. , 2005, Arthritis and rheumatism.

[9]  Sebastian Schneeweiss,et al.  Adjusting for Unmeasured Confounders in Pharmacoepidemiologic Claims Data Using External Information: The Example of COX2 Inhibitors and Myocardial Infarction , 2005, Epidemiology.

[10]  T. MacDonald,et al.  Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease , 2004, Annals of Internal Medicine.

[11]  E. Rimm,et al.  Cardiovascular risk factors in women with and without rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[12]  Sebastian Schneeweiss,et al.  Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. , 2004, American heart journal.

[13]  M. González-Gay,et al.  Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. , 2004, Arthritis and rheumatism.

[14]  P. Libby,et al.  Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? , 2004, Circulation.

[15]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[16]  J. Schwartz,et al.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[17]  I. McInnes,et al.  Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. , 2003, Circulation.

[18]  Samy Suissa,et al.  The nested case-control study in cardiology. , 2003, American heart journal.

[19]  D. O'leary,et al.  Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. , 2003, Arthritis and rheumatism.

[20]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[21]  JoAnn E. Manson,et al.  Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis , 2003, Circulation.

[22]  F. Ruschitzka,et al.  Anti–Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis , 2002 .

[23]  J. Robins,et al.  Methotrexate treatment and mortality in rheumatoid arthritis , 2002, The Lancet.

[24]  James M Robins,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[25]  S. Gabriel,et al.  The epidemiology of rheumatoid arthritis. , 2001, Rheumatic diseases clinics of North America.

[26]  B. Dijkmans,et al.  Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity , 2000, The Lancet.

[27]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[28]  S. Goodman,et al.  The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting Results , 1994, Annals of Internal Medicine.

[29]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[30]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[31]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[32]  Jennifer L. Kelsey,et al.  Methods in Observational Epidemiology , 1986 .

[33]  T C Chalmers,et al.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. , 1978, The New England journal of medicine.

[34]  W. Roberts,et al.  The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: A study of 36 necropsy patients , 1975 .